RT Journal Article
SR Electronic
A1 Summers, Jaye
T1 Teriflunomide Associated With Reductions in Severe MS Relapses
JF MD Conference Express
YR 2015
FD SAGE Publications
VO 15
IS 9
SP 17
OP 18
DO 10.1177/1559897715588463
UL http://mdc.sagepub.com/content/15/9/17.1.abstract
AB The TEMSO and TOWER trials demonstrate that both doses of teriflunomide (7 mg and 14 mg) each significantly reduce the annualized relapse rates in patients with relapsing multiple sclerosis. Post hoc analyses of both trials indicate that only teriflunomide 14 mg significantly reduces the rate of all 5 markers of severe relapse in both studies.